<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OALibJ</journal-id><journal-title-group><journal-title>Open Access Library Journal</journal-title></journal-title-group><issn pub-type="epub">2333-9705</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/oalib.1101645</article-id><article-id pub-id-type="publisher-id">OALibJ-68460</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject><subject> Business&amp;Economics</subject><subject> Chemistry&amp;Materials Science</subject><subject> Computer Science&amp;Communications</subject><subject> Earth&amp;Environmental Sciences</subject><subject> Engineering</subject><subject> Medicine&amp;Healthcare</subject><subject> Physics&amp;Mathematics</subject><subject> Social Sciences&amp;Humanities</subject></subj-group></article-categories><title-group><article-title>
 
 
  Prevalence of Obstructive Sleep Apnoea in Patients with Idiopathic Pulmonary Fibrosis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gabriela</surname><given-names>C. Tabaj</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Daniela</surname><given-names>Visentini</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Patricia</surname><given-names>Malamud</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cecilia</surname><given-names>González Ginestet</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Glenda</surname><given-names>Ernst</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gabriela</surname><given-names>Rando</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mariana</surname><given-names>Salomon</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Georgina</surname><given-names>Gramblicka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Division of Respiratory Medicine, Cetrángolo Hospital, Buenos Aires, Argentina</addr-line></aff><aff id="aff2"><addr-line>Division of Respiratory Medicine, British Hospital, Buenos Aires, Argentina</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>gabrielatabaj@gmail.com(GCT)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>06</month><year>2015</year></pub-date><volume>02</volume><issue>06</issue><fpage>1</fpage><lpage>8</lpage><history><date date-type="received"><day>2</day>	<month>June</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>19</month>	<year>June</year>	</date><date date-type="accepted"><day>25</day>	<month>June</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   Background: Over the last years, increasing attention has been focused on the prevalence of obstructive sleep apnea (OSA) in idiopathic pulmonary fibrosis (IPF). Objective: To determine the prevalence of OSA in a group of patients diagnosed with IPF. Materials and Methods: Analytic retrospective study. Data were collected from the medical records of all patients diagnosed with IPF who had polysomnography requested as part of the study protocol in patients with interstitial lung diseases (ILD). Results: 36 patients were studied, 26 of who were male. The mean age was 67.55 &#177; 6.39 years old. Mean forced vital capacity (FVC) was 2.12 &#177; 0.76 liters. The mean body mass index (BMI) was 28.78 &#177; 4.24. The Epworth Sleepiness Scale (ESS) average was 7.55 &#177; 5.01 and the mean apnea hypopnea index (AHI) was 12.69 &#177; 19.40. Of all the patients studied, 17 (47.22%) had OSA with an AHI ≥ 5. Of these, 9 (25%) had AHI ≥ 10. In the group of patients with OSA (n = 17), 9 (52.94%) had mild OSA (AHI between 5 and 15) and 8 (47.05%) moderate to severe OSA (AHI ≥ 15). Conclusions: In our series of 36 patients with IPF we found a prevalence of OSA of 47.22%. We found no correlation between ESS and the BMI with the presence of OSA in these patients, suggesting that these assessments may be less than optimal screening tools for OSA in IPF. 
  
 
</p></abstract><kwd-group><kwd>Idiopathic Pulmonary Fibrosis</kwd><kwd> Obstructive Sleep Apnea</kwd><kwd> Polisomnography</kwd><kwd> Prevalence</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Idiopathic pulmonary fibrosis (IPF) is a lethal form of chronic, progressive fibrosing interstitial lung disease (ILD) of unknown etiology with a higher prevalence in men over 60 years of age with history of tobacco smoking [<xref ref-type="bibr" rid="scirp.68460-ref1">1</xref>] . IPF is always associated with histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP), has a poor prognosis and is marked by progressive worsening of dyspnea and lung function [<xref ref-type="bibr" rid="scirp.68460-ref2">2</xref>] . The median survival time from diagnosis is 3.5 years [<xref ref-type="bibr" rid="scirp.68460-ref3">3</xref>] .</p><p>The current focus of IPF research is on the molecular genetics of pathologic events likely to occur at the epithelial-mesenchymal interface of the alveolus [<xref ref-type="bibr" rid="scirp.68460-ref4">4</xref>] - [<xref ref-type="bibr" rid="scirp.68460-ref9">9</xref>] . In vitro, studies using lung fibroblast from IPF patients have contributed to the theory that myofibroblasts have a prolonged survival after being activated by an unknown injury, shortened survival of lung epithelial cells, or both [<xref ref-type="bibr" rid="scirp.68460-ref10">10</xref>] . Even though, risk factors have been identified for this disease (e.g. environmental, exposures, genetic determinants, smoking [<xref ref-type="bibr" rid="scirp.68460-ref11">11</xref>] , pollutants, gastro- esophageal reflux [<xref ref-type="bibr" rid="scirp.68460-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.68460-ref13">13</xref>] , occupational exposures, [<xref ref-type="bibr" rid="scirp.68460-ref14">14</xref>] , viral infections [<xref ref-type="bibr" rid="scirp.68460-ref15">15</xref>] and old age [<xref ref-type="bibr" rid="scirp.68460-ref16">16</xref>] ). IPF’s origin and onset are not fully understood. It has been previously suggested that the onset involves alveolar epithelium micro&#173;injuries that lead to dysregulation of cellular homoeostasis in the alveolar epithelial-mesenchymal unit and the reactivation of developmental signaling pathways (e.g. transforming growth factor: TGF-β [<xref ref-type="bibr" rid="scirp.68460-ref17">17</xref>] , wingless-type like (Wnt) [<xref ref-type="bibr" rid="scirp.68460-ref18">18</xref>] , sonic hedgehog (SHH) [<xref ref-type="bibr" rid="scirp.68460-ref19">19</xref>] , and Notch [<xref ref-type="bibr" rid="scirp.68460-ref20">20</xref>] ). The resultant cell dysfunction and death result in progressive scar tissue formation, and eventual distortion of pulmonary anatomical structural relationships with disruption of lung homoeostasis [<xref ref-type="bibr" rid="scirp.68460-ref21">21</xref>] . Some authors hypothesize that IPF originates from long term recurring stretch injury to the peripheral and basal lung in individuals with a genetic predisposition. One of the proposed triggers could be ventilatory efforts associated with obstructive sleep apnea (OSA), which may trigger the process of “aberrant healing”. The generated disease is present in more peripheral areas of the lung based on well-known heightened mechanical stretch factors in this anatomical compartment; in essence a mechanical rather than inflammatory damage [<xref ref-type="bibr" rid="scirp.68460-ref10">10</xref>] .</p><p>Over the last years, attention has been focused on the prevalence of sleep disorders, especially OSA, in patients with IPF. In the general population, the prevalence of OSA is between 5% and 10% [<xref ref-type="bibr" rid="scirp.68460-ref22">22</xref>] . Three prospective studies found the prevalence of OSA in patients with IPF to be excessively larger compared with that reported in the general population, even after adjustment for age, with prevalence of between 59% and 90% [<xref ref-type="bibr" rid="scirp.68460-ref23">23</xref>] - [<xref ref-type="bibr" rid="scirp.68460-ref25">25</xref>] . This increased risk of developing OSA is not restricted to IPF, as studies involving different populations of patients with interstitial diseases, especially systemic sclerosis and sarcoidosis, have shown similar findings [<xref ref-type="bibr" rid="scirp.68460-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.68460-ref27">27</xref>] . To this point, in 2013, we published a prevalence of 48.8% of OSA in patients with ILD, and found that the group of patients with OSA had a higher involvement of nocturnal oximetry measured by CT90 (percentage of total time the layout of the PSG with lower pulse oximetry 90%) [<xref ref-type="bibr" rid="scirp.68460-ref28">28</xref>] .</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>Data were collected from the medical records of all patients diagnosed with IPF (based on criteria identical to those published in the ERS/ATS 2011 guidelines) who were managed at a specialized hospital respiratory diseases on an outpatient basis during the period from January 1, 2010 to December 15, 2014. All idiopathic pulmonary fibrosis (IPF) patients at our institution are studied routinely with polysomnography (PSG) by protocol.</p><p>The following variables were recorded: sex, age, body mass index (BMI), Epworth Sleepiness Scale (ESS), lung function parameters (FVC: Forced Vital Capacity, DLCO: Pulmonary Diffusing Carbon Monoxide), symp- toms consistent with gastro-esophageal reflux (GER), apnea-hypopnea index (AHI) and cumulative percentages of time spent at saturations below 90% (CT 90). The presence of symptoms consistent with GER was assessed by focused interview with the patient. Depending on their AHI, patients were classified as normal (AHI &lt; 5), mild OSA (AHI ≥ 5 but &lt;15) and moderate to severe OSA (AHI ≥ 15). According to WHO obesity criteria, patients were classified as normal (BMI value between 18.5 and 24.9 kg/m<sup>2</sup>), overweight (BMI between 25 and 29.9 kg/m<sup>2</sup>) and obesity (BMI ≥ 30 kg/m<sup>2</sup>) [<xref ref-type="bibr" rid="scirp.68460-ref29">29</xref>] . For the Epworth Sleepiness Scale (ESS), the cutoff used to define daytime sleepiness was 10.</p><p>In all cases, overnight polysomnography was performed using a 23-channel digital system (ATI<sup>&#174;</sup>PENTATEK<sup>&#174;</sup>) and included the following parameters: electroencephalogram, EOG, ECG, nasal thermistor and pressure transducer for measuring airflow, chest and abdominal bands to measure ventilatory effort, continuous oximetry, snoring microphone and monitoring of anterior tibial. Apnea was defined as cessation of airflow (90% compared with baseline) for more than 10 seconds; hypopnea to reduced flow amplitude 50% to 90% associated with oxygen desaturation of at least 3% and/or arousal in the electroencephalogram. OSA is considered an apnea- hypopnea index (AHI) of 5 or more events per hour. CT90 was defined as the percentage of recording time with oxygen saturation below 90%. Significant desaturation was considered a value greater than 20% (CT90 ≥ 20). All polysomnography studies were performed without supplemental oxygen.</p><p>Data from pulmonary function testing were collected in all patients. Spirometry and diffusing capacity of carbon monoxide (DLCO) adjusted to hemoglobin was performed. Pulmonary function test were performed according to ATS/ERS 2005 standards and benchmarks used were NHANES III [<xref ref-type="bibr" rid="scirp.68460-ref30">30</xref>] - [<xref ref-type="bibr" rid="scirp.68460-ref33">33</xref>] .</p><p>The results were expressed as mean and standard deviation. Given the sample size and non-Gaussian distribution, chi-square test was used to compare percentages; the test for nonparametric Mann-Whitney test to compare numeric variables and Spearman test to analyze the correlation of numerical variables. Was considered statistically significant a p value &lt; 0.05. Data were analyzed using Graph-Prism 4.0 software.</p></sec><sec id="s3"><title>3. Results</title><p>In total, 36 patients diagnosed with IPF, 26 men (72.3%) and 10 women (27.7%) were included. The mean age was 67.55 &#177; 6.39 years old. In 32 (88.9%) the diagnosis of IPF was made by high resolution computed tomography (HRCT) showing a “UIP radiological pattern” and in 11.1% (n = 4) by surgical lung biopsy. Eleven patients (30.5%) had chronic oxygen therapy requirements. The mean forced vital capacity (FVC) in absolute values was 2.12 &#177; 0.76 liters and in percentage of predictive value 61.97% &#177; 15.8%. The pulmonary diffusing carbon monoxide (DLCO) average, expressed in absolute values, was 9.80 &#177; 3.69 and percentage of predicted 46.38% &#177; 18.19%. The mean BMI was 28.78 &#177; 4.24. (<xref ref-type="table" rid="table1">Table 1</xref>: Characteristics of patients). The ESS average was 7.55 &#177; 5.01 and the mean AHI of 12.69 &#177; 19.40. Of the total, 17 (47.22%) patients had an AHI ≥ 5 and nine of them (25%) had an AHI ≥ 10.</p><p>Comparing IPF groups with and without OSA we could not find statistically significant differences, except for mean AHI. (<xref ref-type="table" rid="table2">Table 2</xref>: Comparison of patients with and without OSA).</p><p>In the group of patients with OSA (n = 17), 9 (52.94%) had an AHI between 5 and 15 (mild OSA) and 8 (47.05%), an AHI ≥ 15 (OSA moderate to severe) (<xref ref-type="fig" rid="fig1">Figure 1</xref>). When we analyzed the correlation between BMI and CT90 in all our study population (patients without OSA, with mild OSA and with severe OSA), we founded a Spearman r = 0.39 (p = 0.015) (<xref ref-type="fig" rid="fig2">Figure 2</xref>). As regards the analysis of correlation between BMI and AHI, a correlation coefficient of Spearman (r) of 0.31 with p = 0.06 (not significant) (<xref ref-type="fig" rid="fig3">Figure 3</xref>) was found. With regard to the Epworth Sleepiness Scale (ESS), compared with the AHI, a correlation coefficient of Spearman (r) of 0.16 with p = 0.35 (not significant) was found. However, when the correlation between BMI and CT90 only in OSA patients, a Spearman correlation coefficient (r) of 0.01 with a (non-significant) p = 0.39 and high dispersion was observed (<xref ref-type="table" rid="table3">Table 3</xref>: Comparison of the characteristics of the three groups of IPF patients: no OSA, mild OSA and moderate to severe OSA).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Characteristics of the study population</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Age</th><th align="center" valign="middle" >67.55 &#177; 6.39 years old<sup>#</sup></th></tr></thead><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >28.78 &#177; 4.24<sup>#</sup></td></tr><tr><td align="center" valign="middle" >ESS</td><td align="center" valign="middle" >7.55 &#177; 5.01<sup>#</sup></td></tr><tr><td align="center" valign="middle" >FVC (liters)</td><td align="center" valign="middle" >2.12 &#177; 0.76<sup>#</sup></td></tr><tr><td align="center" valign="middle" >FVC (%)</td><td align="center" valign="middle" >61.97% &#177; 15.8%<sup>#</sup></td></tr><tr><td align="center" valign="middle" >DLCO</td><td align="center" valign="middle" >9.80 &#177; 3.69<sup>#</sup></td></tr><tr><td align="center" valign="middle" >DLCO%</td><td align="center" valign="middle" >46.38% &#177; 18.19%<sup>#</sup></td></tr><tr><td align="center" valign="middle" >Requirements LTOT (%)</td><td align="center" valign="middle" >11 (30.5%)</td></tr><tr><td align="center" valign="middle" >AHI</td><td align="center" valign="middle" >12.69 &#177; 19.40<sup>#</sup></td></tr><tr><td align="center" valign="middle" >CT 90</td><td align="center" valign="middle" >34.26 &#177; 37.94<sup>#</sup></td></tr><tr><td align="center" valign="middle" >CT90 ≥ 20 (%)</td><td align="center" valign="middle" >18 (50.61%)</td></tr><tr><td align="center" valign="middle" >AHI ≥ 5 (%)</td><td align="center" valign="middle" >17 (47.22%)</td></tr></tbody></table></table-wrap><p><sup>#</sup>Mean &#177; standard deviation.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of the characteristics of the groups of IPF patients with and without OSA</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >AIH &lt; 5 n = 19 (52.77%)</th><th align="center" valign="middle" >AIH ≥ 5 (OSA) n = 17 (47.22%)</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >Age (years old)</td><td align="center" valign="middle" >67.68 &#177; 6.14<sup>#</sup></td><td align="center" valign="middle" >67.41 &#177; 6.85<sup>#</sup></td><td align="center" valign="middle" >p = 0.90</td></tr><tr><td align="center" valign="middle" >Men</td><td align="center" valign="middle" >14 (73.68%)</td><td align="center" valign="middle" >12 (70.58%)</td><td align="center" valign="middle" >p = 0.86</td></tr><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >28.18 &#177; 4.09<sup>#</sup></td><td align="center" valign="middle" >29.45 &#177; 4.43<sup>#</sup></td><td align="center" valign="middle" >p = 0.30</td></tr><tr><td align="center" valign="middle" >ESS</td><td align="center" valign="middle" >6.89 &#177; 4.96<sup>#</sup></td><td align="center" valign="middle" >8.29 &#177; 5.10<sup>#</sup></td><td align="center" valign="middle" >p = 0.33</td></tr><tr><td align="center" valign="middle" >FVC (liters)</td><td align="center" valign="middle" >2.07 &#177; 0.68<sup>#</sup></td><td align="center" valign="middle" >2.16 &#177; 0.85<sup>#</sup></td><td align="center" valign="middle" >p = 0.89</td></tr><tr><td align="center" valign="middle" >FVC%</td><td align="center" valign="middle" >61.68 &#177; 14.64<sup>#</sup></td><td align="center" valign="middle" >62.29 &#177; 17.59<sup>#</sup></td><td align="center" valign="middle" >p = 0.91</td></tr><tr><td align="center" valign="middle" >DLCO</td><td align="center" valign="middle" >10.23 &#177; 4.20<sup>#</sup></td><td align="center" valign="middle" >9.31 &#177; 3.07<sup>#</sup></td><td align="center" valign="middle" >p = 0.47</td></tr><tr><td align="center" valign="middle" >DLCO%</td><td align="center" valign="middle" >47.55 &#177; 19.24<sup>#</sup></td><td align="center" valign="middle" >45.06 &#177; 17.41<sup>#</sup></td><td align="center" valign="middle" >p = 0.69</td></tr><tr><td align="center" valign="middle" >LTOT requirements</td><td align="center" valign="middle" >6 (31.57%)</td><td align="center" valign="middle" >5 (29.41%)</td><td align="center" valign="middle" >p = 0.82</td></tr><tr><td align="center" valign="middle" >Gastro-esophageal reflux</td><td align="center" valign="middle" >5 (26.31%)</td><td align="center" valign="middle" >6 (32.29%)</td><td align="center" valign="middle" >p = 0.82</td></tr><tr><td align="center" valign="middle" >AHI</td><td align="center" valign="middle" >2.33 &#177; 1.30<sup>#</sup></td><td align="center" valign="middle" >24.27 &#177; 23.48<sup>#</sup></td><td align="center" valign="middle" >p = 0.0003</td></tr><tr><td align="center" valign="middle" >CT90</td><td align="center" valign="middle" >31.82 &#177; 41.14<sup>#</sup></td><td align="center" valign="middle" >37 &#177; 35.05<sup>#</sup></td><td align="center" valign="middle" >p = 0.68</td></tr><tr><td align="center" valign="middle" >CT90 ≥ 20</td><td align="center" valign="middle" >8 (42.10%)</td><td align="center" valign="middle" >10 (58.82%)</td><td align="center" valign="middle" >p = 0.50</td></tr></tbody></table></table-wrap><p><sup>#</sup>Mean &#177; standard deviation.</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Comparison of AHI between the tree groups of patients</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/68460x5.png"/></fig><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> Correlation between BMI and CT90 in studied po- pulation. p = 0.015</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/68460x6.png"/></fig><fig id="fig3"  position="float"><label><xref ref-type="fig" rid="fig3">Figure 3</xref></label><caption><title> Correlation between BMI and AHI in studied population. p = 0.06</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/68460x7.png"/></fig><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of the characteristics of the tree groups of IPF patients: no OSA, mild OSA and moderate to severe OSA</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >Patients without OSA AIH &lt; 5 n = 19 (52.77%)</th><th align="center" valign="middle" >Patients with mild OSA AIH between 5 and 15 n = 9 (25%)</th><th align="center" valign="middle" >Patients with moderate to severe OSA AHI ≥ 15 n = 8 (22.22%)</th></tr></thead><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >28.18 &#177; 4.09<sup>#</sup></td><td align="center" valign="middle" >27.42 &#177; 4.36<sup>#</sup></td><td align="center" valign="middle" >31.75 &#177; 3.45<sup>#</sup></td></tr><tr><td align="center" valign="middle" >Gastro-esophageal reflux</td><td align="center" valign="middle" >5 (26.31%)</td><td align="center" valign="middle" >3 (33.33%)</td><td align="center" valign="middle" >3 (37.5%)</td></tr><tr><td align="center" valign="middle" >ESS</td><td align="center" valign="middle" >6.89 &#177; 4.96<sup>#</sup></td><td align="center" valign="middle" >7.11 &#177; 3.51<sup>#</sup></td><td align="center" valign="middle" >9.62 &#177; 6.45<sup>#</sup></td></tr><tr><td align="center" valign="middle" >FVC</td><td align="center" valign="middle" >2.07 &#177; 0.68<sup>#</sup></td><td align="center" valign="middle" >1.97 &#177; 0.58<sup>#</sup></td><td align="center" valign="middle" >2.38 &#177; 1.09<sup>#</sup></td></tr><tr><td align="center" valign="middle" >FVC%</td><td align="center" valign="middle" >61.68 &#177; 14.64<sup>#</sup></td><td align="center" valign="middle" >61.11 &#177; 13.16<sup>#</sup></td><td align="center" valign="middle" >63.62 &#177; 22.49<sup>#</sup></td></tr><tr><td align="center" valign="middle" >DLCO</td><td align="center" valign="middle" >10.23 &#177; 4.20</td><td align="center" valign="middle" >8.00 &#177; 2.39</td><td align="center" valign="middle" >10.99 &#177; 3.18</td></tr><tr><td align="center" valign="middle" >DLCO%</td><td align="center" valign="middle" >47.55 &#177; 19.24</td><td align="center" valign="middle" >40.77 &#177; 16.44</td><td align="center" valign="middle" >50.57 &#177; 18.29</td></tr><tr><td align="center" valign="middle" >CT90 mean</td><td align="center" valign="middle" >31.82 &#177; 41.14</td><td align="center" valign="middle" >44.5 &#177; 44.08</td><td align="center" valign="middle" >28.56 &#177; 20.8</td></tr><tr><td align="center" valign="middle" >AHI</td><td align="center" valign="middle" >2.33 &#177; 1.30<sup>#</sup></td><td align="center" valign="middle" >7.30 &#177; 3.09<sup>#</sup></td><td align="center" valign="middle" >43.37 &#177; 21.5<sup>#</sup></td></tr><tr><td align="center" valign="middle" >LTOT requirements</td><td align="center" valign="middle" >6 (31.57%)</td><td align="center" valign="middle" >4 (44.44%)</td><td align="center" valign="middle" >1 (12.5%)</td></tr></tbody></table></table-wrap><p><sup>#</sup>Mean &#177; standard deviation.</p></sec><sec id="s4"><title>4. Discussion</title><p>The prevalence of OSA in patients with ILD remains a controversial issue, especially regarding mechanism and relevance in these diseases. Recent studies have shown a high prevalence in IPF [<xref ref-type="bibr" rid="scirp.68460-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.68460-ref34">34</xref>] [<xref ref-type="bibr" rid="scirp.68460-ref35">35</xref>] despite previous studies describing a lower frequency of sleep-disordered breathing in patients with IPF [<xref ref-type="bibr" rid="scirp.68460-ref36">36</xref>] [<xref ref-type="bibr" rid="scirp.68460-ref37">37</xref>] .</p><p>Using night polysomnography (PSG) a higher prevalence of obstructive respiratory events associated with sleep has been described. According to a paper published by Mermigkisin 2010 [<xref ref-type="bibr" rid="scirp.68460-ref25">25</xref>] , the prevalence of OSA with AHI ≥ 5 was 59% in patients with IPF and the respiratory events in REM phase correlated with the TLC whereas DLCO correlated with the average oximetry during sleep. Recently, it have been released a study of 50 patients with ILD, 17 of them with IPF, where the frequency of OSA was 68%. The mean AHI was 11.4 &#177; 12.5 and OSA was more common in patients with IPF (p = 0.009) [<xref ref-type="bibr" rid="scirp.68460-ref26">26</xref>] .</p><p>In recent years there have been several studies that assessed the prevalence of OSA in patients with IPF (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>Remains unclear the real question about if OSA is a cause or a consequence of IPF. Different research studies are trying to know the possible mechanicals triggers responsible of the aberrant repair in IPF, one raising hypothesis could be that the M&#252;ller’s maneuver (the reverse of Valsalva’s maneuver) could contribute with the injure of the alveolar epithelial cells. In OSA, this maneuver is a recurrent fact: after a forced expiration, an attempt at inspiration is made with closed mouth and nose, whereby the negative pressure in the chest and lungs is made</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Publications about prevalence of OSA in IPF</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Author and publication year</th><th align="center" valign="middle" >Population</th><th align="center" valign="middle" >Prevalence of OSA</th><th align="center" valign="middle" >Mean BMI</th></tr></thead><tr><td align="center" valign="middle" >Mermigkis 2007 [<xref ref-type="bibr" rid="scirp.68460-ref34">34</xref>]</td><td align="center" valign="middle" >Retrospective study 18 patients with IPF</td><td align="center" valign="middle" >11 (61%) had OSA</td><td align="center" valign="middle" >33.2</td></tr><tr><td align="center" valign="middle" >Lancaster 2009 [<xref ref-type="bibr" rid="scirp.68460-ref24">24</xref>]</td><td align="center" valign="middle" >Prospective study 50 patients with IPF</td><td align="center" valign="middle" >44 (88%) had OSA: 20% mild OSA and 68% moderate-severe OSA</td><td align="center" valign="middle" >32.2</td></tr><tr><td align="center" valign="middle" >Mermigkis 2010 [<xref ref-type="bibr" rid="scirp.68460-ref25">25</xref>]</td><td align="center" valign="middle" >Prospective study 34 patients with FPI</td><td align="center" valign="middle" >20 (59%) had OSA: 44% mild OSA land 15% moderate OSA</td><td align="center" valign="middle" >27.3</td></tr><tr><td align="center" valign="middle" >Kolilekas et al. 2013 [<xref ref-type="bibr" rid="scirp.68460-ref23">23</xref>]</td><td align="center" valign="middle" >31 patients with FPI</td><td align="center" valign="middle" >28 (90%) had OSA: 38% mild OSA and 51.6% moderate-severe OSA</td><td align="center" valign="middle" >28.7</td></tr><tr><td align="center" valign="middle" >Pihtili et al. 2013 [<xref ref-type="bibr" rid="scirp.68460-ref26">26</xref>]</td><td align="center" valign="middle" >Prospective. Patients with BMI ≥ 30 were excluded</td><td align="center" valign="middle" >In patients with IPF n = 14, 82% had OSA</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>very subatmospheric. This situation may be related with epithelial cell stretching, endothelial cell stress failure, hypoxia-reoxygenation damage and GER, all factors associated with the mechanisms of the pathophysiology in IPF [<xref ref-type="bibr" rid="scirp.68460-ref10">10</xref>] . In agree with Mermigkis and his coworkers, we think that is crucial to try to identify and treat OSA in patients with IPF [<xref ref-type="bibr" rid="scirp.68460-ref38">38</xref>] .</p><p>Although some retrospective studies have suggested an association between the degree of lung restriction and risk and severity of sleep-related disorders in patients with IPF, this has not been demonstrated in prospective studies with larger numbers of patients [<xref ref-type="bibr" rid="scirp.68460-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.68460-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.68460-ref34">34</xref>] . The only correlation between lung volumes and PSG parameters reported by Mermigkis and coworkers was in total lung capacity (TLC) and index apnea hypopnea REM (AHI) sleep. In our study, we found no statistically significant differences between patients with IPF with and without OSA with regard to lung function parameters.</p><p>Excessive daytime sleepiness measured by the Epworth Sleepiness Scale (ESS) has not proven to be a good predictor of OSA in patients with ILD [<xref ref-type="bibr" rid="scirp.68460-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.68460-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.68460-ref26">26</xref>] . In our study, comparing the ESS and AHI the Spearman correlation coefficient (r) was 0.16 (with a non-significant p) which would mean that the ESS is not a good predictor of OSA in patients with IPF.</p><p>We have published a series of 41 patients with ILD, of which 48.8% had an AHI ≥ 5 and 20% had AHI ≥ 15 [<xref ref-type="bibr" rid="scirp.68460-ref28">28</xref>] . As in this series, ESS did not correlated with the presence of OSA. Although in our group, 11 patients (30.5%) required long term oxygen therapy (LTOT) and 18 (50.61%) presented a CT90 ≥ 20.</p><p>As previously published by Kolilekas et al. [<xref ref-type="bibr" rid="scirp.68460-ref23">23</xref>] , we found no relationship between BMI and PSG parameters (AHI and CT90). In our series, the correlation between BMI and CT90 was 0.39 with r (p = 0.015) (<xref ref-type="fig" rid="fig2">Figure 2</xref>) and the correlation between BMI and AHI was r 0.31 (p = 0.06) (<xref ref-type="fig" rid="fig3">Figure 3</xref>); suggesting the presence of apnea or nocturnal desaturation in this group of patients was related to the presence of obesity.</p><p>Recent publications suggest that sleep breathing disorders are common in patients with IPF and other diffuse parenchymal lung diseases and that these may be under diagnosed. In our series of 36 patients with IPF we found a prevalence of OSA of 47.22%. No correlation between ESS and the BMI with the presence of OSA in patients with IPF, making both poor screening tools.</p><p>Our study has several limitations such as their retrospective characteristics and the limited number of patients. However it is a study in one center specializing in respiratory diseases where polysomnography is a standard of care in patients with IPF.</p><p>There are still many unanswered questions. Does the presence of OSA have real impact on the natural history of patients with IPF? Are there potential benefits of treatment in these individuals using positive pressure ventilation and oxygen therapy? Would therapy have a measurable effect on the underlying disease or on the quality of life? Further studies are needed to clarify these questions and hopefully provide guidance to those involved with the care of patients with IPF.</p></sec><sec id="s5"><title>5. Conclusion</title><p>In our series of 36 patients with IPF we found a prevalence of OSA of 47.22%. We found no correlation between ESS and the BMI with the presence of OSA in these patients, suggesting that these assessments may be less than optimal screening tools for OSA in IPF.</p></sec><sec id="s6"><title>Cite this paper</title><p>Gabriela C. Tabaj,Daniela Visentini,Patricia Malamud,Cecilia Gonz&#225;lez Ginestet,Glenda Ernst,Gabriela Rando,Mariana Salomon,Georgina Gramblicka, (2015) Prevalence of Obstructive Sleep Apnoea in Patients with Idiopathic Pulmonary Fibrosis. Open Access Library Journal,02,1-8. doi: 10.4236/oalib.1101645</p></sec></body><back><ref-list><title>References</title><ref id="scirp.68460-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Cottin, V. (2014) Idiopathic Pulmonary Fibrosis. La Revue du Praticien, 64, 923-8, 930-2.</mixed-citation></ref><ref id="scirp.68460-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Raghu, G., Collard, H., Egan, J., et al. (2011) An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence Based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 183, 788-824. http://dx.doi.org/10.1164/rccm.2009-040GL</mixed-citation></ref><ref id="scirp.68460-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Vancheri, C., Failla, M., Crimi, N., et al. (2010) Idiopathic Pulmonary Fibrosis: A Disease with Similarities and Links to Cancer Biology. European Respiratory Journal, 35, 496-504. http://dx.doi.org/10.1183/09031936.00077309</mixed-citation></ref><ref id="scirp.68460-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chilosi, M., Doglioni, C., Murer, B., et al. (2010) Epithelial Stem Cell Exhaustion in the Pathogenesis of Idiopathic Pulmonary Fibrosis. Sarcoidosis, Vasculitis and Diffuse Lung Diseases, 27, 7-18.</mixed-citation></ref><ref id="scirp.68460-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ding, Q., Luckhardt, T., Hecker, L., et al. (2011) New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis. Drugs, 71, 981-1001. http://dx.doi.org/10.2165/11591490-000000000-00000</mixed-citation></ref><ref id="scirp.68460-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Sisson, T.H., Mendez, M., Choi, K., et al. (2009) Targeted Injury of Type II Alveolar Epithelial Cells Induces Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 181, 254-263.http://dx.doi.org/10.1164/rccm.200810-1615OC</mixed-citation></ref><ref id="scirp.68460-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Selman, M. and Pardo, A. (2006) Role of Epithelial Cells in Idiopathic Pulmonary Fibrosis: From Innocent Targets to Serial Killers. Proceedings of the American Thoracic Society, 3, 364-372. http://dx.doi.org/10.1513/pats.200601-003TK</mixed-citation></ref><ref id="scirp.68460-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Thannickal, V.J. and Horowitz, J.C. (2006) Evolving Concepts of Apoptosis in Idiopathic Pulmonary Fibrosis. Proceedings of the American Thoracic Society, 3, 350-356. http://dx.doi.org/10.1513/pats.200601-001TK</mixed-citation></ref><ref id="scirp.68460-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Cronkhite, J.T., Xing, C., Raghu, G., et al. (2008) Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 178, 729-737. http://dx.doi.org/10.1164/rccm.200804-550OC</mixed-citation></ref><ref id="scirp.68460-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Leslie, K.O. (2012) Idiopathic Pulmonary Fibrosis May Be a Disease of Recurrent, Tractional Injury to the Periphery of the Aging Lung a Unifying Hypothesis Regarding Etiology and Pathogenesis. Archives of Pathology Laboratory Medicine, 36, 591-600. http://dx.doi.org/10.5858/arpa.2011-0511-OA</mixed-citation></ref><ref id="scirp.68460-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Oh, C.K., Murray, L.A. and Molno, N.A. (2012) Smoking and Idiopathic Pulmonary Fibrosis. Pulmonary Medicine, 2012, Article ID: 808260.</mixed-citation></ref><ref id="scirp.68460-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Raghu, G., Freudenberger, T.D., Yang, S., et al. (2006) High Prevalence of Abnormal Acid Gastro-Esophageal Reux in Idiopathic Pulmonary Fibrosis. European Respiratory Journal, 27, 136-142. http://dx.doi.org/10.1183/09031936.06.00037005</mixed-citation></ref><ref id="scirp.68460-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J.S., Ryu, J.H., Elicker, B.M., et al. (2011) Gastroesophageal Reflux Therapy Is Associated with Longer Survival in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 184, 1390-1394. http://dx.doi.org/10.1164/rccm.201101-0138OC</mixed-citation></ref><ref id="scirp.68460-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Taskar, V.S. and Coultas, D.B. (2006) Is Idiopathic Pulmonary Fibrosis an Environmental Disease? Proceedings of the American Thoracic Society, 3, 293-298. http://dx.doi.org/10.1513/pats.200512-131TK</mixed-citation></ref><ref id="scirp.68460-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Lasithiotaki, I., Antoniou, K.M., Vlahava, V.M., et al. (2011) Detection of Herpes Simplex Virus Type-1 in Patients with Fibrotic Lung Diseases. PLoS ONE, 6, e27800. http://dx.doi.org/10.1371/journal.pone.0027800</mixed-citation></ref><ref id="scirp.68460-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Faner, R., Rojas, M., Macnee, W., et al. (2012) Abnormal Lung Aging in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 186, 306-313. http://dx.doi.org/10.1164/rccm.201202-0282PP</mixed-citation></ref><ref id="scirp.68460-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Wynn, T.A. (2011) Integrating Mechanisms of Pulmonary Brosis. The Journal of Experimental Medicine, 208, 1339-1350. http://dx.doi.org/10.1084/jem.20110551</mixed-citation></ref><ref id="scirp.68460-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Konigsho, M. and Eickelberg, O. (2010) WNT Signaling in Lung Disease: A Failure or a Regeneration Signal? American Journal of Respiratory Cell and Molecular Biology, 42, 21-31. http://dx.doi.org/10.1165/rcmb.2008-0485TR</mixed-citation></ref><ref id="scirp.68460-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Crosby, L.M. and Waters, C.M. (2010) Epithelial Repair Mechanisms in the Lung. American Journal of Physiology-Lung Cellular and Molecular Physiology, 298, 715-731. http://dx.doi.org/10.1152/ajplung.00361.2009</mixed-citation></ref><ref id="scirp.68460-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Aoyagi-Ikeda, K., Maeno, T., Matsui, H., et al. (2011) Notch Induces Myofibroblast Differentiation of Alveolar Epithelial Cells via Transforming Growth Factor-{beta}-Smad3 Pathway. American Journal of Respiratory Cell and Molecular Biology, 45, 136-144.</mixed-citation></ref><ref id="scirp.68460-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Fernandez, I.E. and Eickelberg, O. (2012) New Cellular and Molecular Mechanisms of Lung Injury and Fibrosis in Idiopathic Pulmonary Fibrosis. The Lancet, 380, 680-688. http://dx.doi.org/10.1016/S0140-6736(12)61144-1</mixed-citation></ref><ref id="scirp.68460-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Punjabi, N.M. (2008) The Epidemiology of Adult Obstructive Sleep Apnea. Proceedings of the American Thoracic Society, 5, 136-143. http://dx.doi.org/10.1513/pats.200709-155MG</mixed-citation></ref><ref id="scirp.68460-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kolilekas, L., Manali, E., Vlami, K.A., et al. (2013) Sleep Oxygen Desaturation Predicts Survival in Idiopathic Pulmonary Fibrosis. Journal of Clinical Sleep Medicine, 9, 593-596. http://dx.doi.org/10.5664/jcsm.2758</mixed-citation></ref><ref id="scirp.68460-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Lancaster, L.H., Mason, W.R., Parnell, J.A., et al. (2009) Obstructive Sleep Apnea Is Common in Idiopathic Pulmonary Fibrosis. Chest, 136, 772-778. http://dx.doi.org/10.1378/chest.08-2776</mixed-citation></ref><ref id="scirp.68460-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Mermigkis, C., Stagaki, E., Tryfon, S., et al. (2010) How Common Is Sleep-Disordered Breathing in Patients with Idiopathic Pulmonary Fibrosis? Sleep and Breathing, 14, 387-390. http://dx.doi.org/10.1007/s11325-010-0336-5</mixed-citation></ref><ref id="scirp.68460-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Pihtili, A., Bingol, Z., Kiyan, E., et al. (2013) Obstructive Sleep Apnea Is Common in Patients with Interstitial Lung Disease. Sleep and Breathing, 17, 1281-1288. http://dx.doi.org/10.1007/s11325-013-0834-3</mixed-citation></ref><ref id="scirp.68460-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Turner, G.A., Lower, E.E., Corser, B.C., et al. (1997) Sleep Apnea in Sarcoidosis. Sarcoidosis, Vasculitis and Diffuse Lung Diseases, 14, 61-64.</mixed-citation></ref><ref id="scirp.68460-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Tabaj, G., Visentini, D., Grodnitzky, L., et al. (2013) Frecuencia de Trastornos Respiratorios del Sue&amp;#241;o en Pacientes con Enfermedad Difusa del Parénquima Pulmonar. Revista Americana de Medicina Respiratoria, 13, 12-18.</mixed-citation></ref><ref id="scirp.68460-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">(1998) Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: Executive Summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. The American Journal of Clinical Nutrition, 68, 899-917.</mixed-citation></ref><ref id="scirp.68460-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Miller, M.R., Hankinson, J., Brusasco, V., et al. (2005) Standardisation of Spirometry. European Respiratory Journal, 26, 319-338. http://dx.doi.org/10.1183/09031936.05.00034805</mixed-citation></ref><ref id="scirp.68460-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">MacIntyre, N., Crapo, R.O., Viegi, G., et al. (2005) Standardization of the Single-Breath Determination of Carbon Monoxide Uptake in the Lung. European Respiratory Journal, 26, 720-735. http://dx.doi.org/10.1183/09031936.05.00034905</mixed-citation></ref><ref id="scirp.68460-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Pellegrino, R., Viegi, G., Brusasco, V., et al. (2005) Interpretative Strategies for Lung Function Tests. European Respiratory Journal, 26, 948-968. http://dx.doi.org/10.1183/09031936.05.00035205</mixed-citation></ref><ref id="scirp.68460-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Hankinson, J.L., Odencrantz, J.R. and Fedan, K.B. (1999) Spirometric Reference Values from a Sample of the General U.S. Population. American Journal of Respiratory and Critical Care Medicine, 159, 179-187. http://dx.doi.org/10.1164/ajrccm.159.1.9712108</mixed-citation></ref><ref id="scirp.68460-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Mermigkis, C., Chapman, J., Golish, J., et al. (2007) Sleep-Related Breathing Disorders in Patients with Idiopathic Pulmonar Fibrosis. Lung, 185, 173-178. http://dx.doi.org/10.1007/s00408-007-9004-3</mixed-citation></ref><ref id="scirp.68460-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Mermigkis, C., Stagaki, E., Amfilochiou, A., et al. (2009) Sleep Quality and Associated Daytime Consequences in Patients with Idiopathic Pulmonary Fibrosis. Medical Principles and Practice, 18, 10-15. http://dx.doi.org/10.1159/000163039</mixed-citation></ref><ref id="scirp.68460-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Perez-Padilla, R., West, P., Lertzman, M., et al. (1985) Breathing during Sleep in Patients with Interstitial Lung Disease. American Review of Respiratory Disease, 132, 224-229.</mixed-citation></ref><ref id="scirp.68460-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Bye, P., Issa, F., Berthon-Jones, M., et al. (1984) Studies of Oxygenation during Sleep in Patients with Interstitial Lung Disease. American Review of Respiratory Disease, 129, 27-32.</mixed-citation></ref><ref id="scirp.68460-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Mermigkis, C., Bouloukaki, I., Antoniou, K., et al. (2015) Obstructive Sleep Apnea Should Be Treated in Patients with Idiopathic Pulmonary Fibrosis. Sleep and Breathing, 19, 385-391. http://dx.doi.org/10.1007/s11325-014-1033-6</mixed-citation></ref></ref-list></back></article>